March 2007
Worldwide Biotech;Mar2007, Vol. 19 Issue 3, p3
Trade Publication
The article reports on a clearance given by the U.S. Food and Drug Administration to BioMS Medical Corp., for the phase III clinical trial of its multiple sclerosis drug. BioMS is investigating the use of MBP8298 as a treatment for patients with secondary progressive multiple sclerosis. Kevin Giese, president and chief executive officer of BioMS Medical, gave details of the estimated number of people in the U.S. with multiple sclerosis.


Related Articles

  • BioMS: Dirucotide Phase II Data Show 'Nice Signal' Despite Miss. Boggs, Jennifer // BioWorld Today;2/2/2009, Vol. 20 Issue 20, p2 

    The article reports that data regarding disease progression could point to the success of BioMS Medical Corp.'s multiple sclerosis (MS) drug dirucotide. BioMS president and chief executive officer (CEO) Kevin Giese notes that results from the Phase II study showed that dirucotide missed the...

  • BioMS, Lilly Scratch Heads Over Dirucotide Phase III MS Blowup. Boggs, Jennifer // BioWorld Today;7/29/2009, Vol. 20 Issue 144, p1 

    The article reports on the 85.4% decline of BioMS Medical Corp.'s stock on July 28, 2009. This is attributed to the failure of the company's only drug candidate, dirucotide, to delay disease progression over placebo in a Phase III trial in secondary progressive multiple sclerosis patients. With...

  • GlaxoSmithKline: COX-II fallout dents MS hopes.  // PharmaWatch: Monthly Review;May2005, Vol. 4 Issue 5, p15 

    The article reports on the suspension of the phase II clinical trials of pharmaceutical company GlaxoSmithKline's multiple sclerosis and Crohn's disease drug 683-699 by the U.S. Food and Drug Administration (FDA). The FDA pointed out that the drug displayed similar mechanism with the recently...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Apr2006, Vol. 5 Issue 4, p11 

    The article reports developments related to multiple sclerosis medication in the U.S. A unanimous decision on the reinstatement of multiple sclerosis treatment, Tysabri, was made by the 12 member advisory panel to the Food and Drug Administration. Meanwhile, the phase II study of BioMS Medical...

  • BioMS wins FDA fast track designation for multiple sclerosis drug.  // PharmaWatch: CNS;Oct2008, Vol. 7 Issue 10, p9 

    The article reports on the support of the U.S. Food and Drug Administration (FDA) for BioMS Medical Corp.'s multiple sclerosis drug dirucotide in 2008. The biotechnology company reveals its pleasure for FDA's fast track designation for its dirucotide for the treatment of secondary progressive...

  • The what's and why's of clinical trials. Reingold, Stephen // Inside MS;Winter/Spring95, Vol. 13 Issue 1, p4 

    Focuses on the mechanics of clinical trials in the study of multiple sclerosis (MS). Features of a clinical trial include unpredictability; Difference in effect of different agents on various types of MS; Effect of motivation to treatment; Phases of a clinical trial; Criteria for enrolling in...

  • BioMS Medical: potential to broaden MS treatment options.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p4 

    The article reports on the move of BioMS Medical to initiate an open-label extension of its MAESTRO-01 pivotal phase II/III trial of MBP-8298 in patients with secondary progressive multiple sclerosis. It states that MAESTRO-02 was conducted in Canada and Europe and will provide additional...

  • Dirucotide Data Show 'Nice Signal' Despite Miss.  // Bioworld Week;2/9/2009, Vol. 17 Issue 6, p2 

    The article reports on the determination of BioMS Medical Corp. in Edmonton, Alberta, despite its dirucotide data failure. According to the article, the company fell down for about 30.3% due to its relapse rate failure to its Phase II study on patients with multiple sclerosis (MS). However, the...

  • BIOMS MEDICAL RECEIVES MILESTONE PAYMENT FROM ELI LILLY.  // Biotech Financial Reports;Oct2008, Vol. 15 Issue 10, p6 

    The article announces that BioMS Medical Corp. has received the US$10 million milestone payment from its partner, Eli Lilly and Co. The milestone payment is based on the positive review of the scheduled interim analysis of the pivotal phase II/III Canadian and European trial of dirucotide....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics